News | November 17, 2008

Stereotaxis Begins European Release of Magnetic Irrigated Catheter

November 18, 2008 - Stereotaxis Inc. this week launched its partnered magnetic irrigated catheter at centers in Europe, after its strong performance in the partner's recently concluded external evaluation.

During the external evaluation, clinicians at nine centers in Europe and Canada performed 92 procedures with the magnetic irrigated catheter, approximately 75 percent of which were complex left-sided procedures. Stereotaxis said the catheter exceeded all clinical end points tested during this evaluation period. Additionally, mean time to complete mapping and ablation was 20 percent below documented manual times, and the catheter demonstrated an exceptional safety profile.

"As one of the original evaluation sites for the magnetic irrigated catheter, we were among the first to see its clear clinical advantages," said Gerhard Hindricks, M.D., of Herzentrum Leipzig GmbH in Leipzig. "Having now performed additional cases since its re-introduction, we're delighted by its performance relative to navigation and lesion formation and we're very excited to participate in its commercial release."

Dr. Karl Heinz-Kuck from St. Georg Allgemeines Krankenhaus in Hamburg said, "Its superb maneuverability provides precise positioning even at sites difficult to reach within the heart, and together with the catheter's stability this led to a high success rate."

For more information: www.stereotaxis.com


Related Content

News | Cardiovascular Clinical Studies

April 16, 2024 β€” CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 β€” Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 β€” People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 β€” Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 β€” One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 β€” The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 β€” Administering tranexamic acid (TxA), a drug used to reduce bleeding during heart surgery, topically ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 β€” Using a web application to qualify individuals for treatment with a nonprescription statin closely ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 β€” People with a small aortic annulus, a part of the heart’s anatomy where the left ventricle meets the ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 8, 2024 β€” People with diabetes who had suffered a heart attack derived no clinical benefit from edetate disodium ...

Home April 08, 2024
Home
Subscribe Now